Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.